Roche won expanded FDA clearance tied to Jazz Pharmaceuticals’ HER2-directed therapy Ziihera, extending test eligibility for first-line HER2-positive stomach cancer patients. The update covers use of Roche’s PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH DNA Probe Cocktail to assess HER2 status in metastatic gastroesophageal adenocarcinoma. In parallel, new molecular imaging work reported that a fluorine-18-labeled somatostatin receptor PET tracer, [18F]SiTATE, produced high-contrast images of meningiomas in a 37-patient retrospective study. Higher imaging contrast can improve lesion delineation, which is critical when planning diagnosis and treatment decisions. Together, the moves highlight a continued push for companion diagnostics and higher-specificity imaging modalities that narrow patient selection for targeted therapies and improve tumor visualization.